Indian Journal of Psychiatry
April 1, 2010
T. Rao, Chittaranjan Andrade
Byline: T.S. Rao, Chittaranjan. Andrade Antidepressant drugs have traditionally addressed the monoamine triumvirate: serotonin, noradrenaline, and dopamine. There have been predominantly two mechanisms recruited in drug action - inhibition of monoamine reuptake and inhibition of intravesicular monoamine catabolism. Tianeptine, which increases the synaptic reuptake of serotonin, and mirtazapine,...
Journal of Psychopharmacology
February 1, 2010
D. Dickerson, Brian Pittman, E. Ralevski et al.
The γ-aminobutyric acid-A (GABA A ) and N-methyl-D-aspartate (NMDA) receptors mediate aspects of the behavioural effects of alcohol. Prior studies reported drugs that block NMDA receptors or facilitate GABA A receptor function produce ethanol-like effects in humans. The purpose of this study was to compare the ethanol-related effects of two pharmacological agents with known NMDA and GABA A...
Biological Psychiatry
January 15, 2010
Marije Aan Het Rot, Katherine A. Collins, James W. Murrough et al.
A single subanesthetic (intravenous) IV dose of ketamine might have rapid but transient antidepressant effects in patients with treatment-resistant depression (TRD). Here we tested the tolerability, safety, and efficacy of repeated-dose open-label IV ketamine (six infusions over 12 days) in 10 medication-free symptomatic patients with TRD who had previously shown a meaningful antidepressant...
Addiction
January 2010
Celia J. A. Morgan, Leslie Muetzelfeldt, Helen Valerie Curran
'Recreational' use of ketamine is spreading rapidly among young people. In healthy individuals an acute dose of the N-methyl D-aspartate (NMDA) receptor antagonist ketamine induces marked psychosis-like effects and cognitive impairments, but little is known about the long-term effects of the drug. To evaluate the long-term neuropsychiatric or cognitive consequences. A total of 150 individuals...
The Journal of Neuropsychiatry and Clinical Neurosciences
2010
Michael Messer, Irina V Haller, Pamela Larson et al.
Treatment-resistant depression often leads to increased morbidity and disability. The authors report the use of ketamine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist, in two patients with treatment-resistant depression. Multiple ketamine treatments may provide an effective rapid antidepressant effect with prolonged benefit.
Pharmacopsychiatry
December 11, 2009
Georgios Paslakis, Morin Gilles, Andreas Meyer‐Lindenberg et al.
66 citations
We intended to assess safety, response to treatment and time to response of 1.25 mg/kg oral S-ketamine as add-on to standard antidepressants in four depressed patients. Two patients with melancholic depression responded early and stayed in remission, while two patients with distinct somatic symptoms, chronicity or atypical features did not respond. The limited number of patients does not allow...
Psychological Medicine
December 9, 2009
Jiřı́ Horáček, Martin Brunovský, Tomáš Novák et al.
42 citations
BACKGROUND: Theta cordance is a novel quantitative electroencephalography (QEEG) measure that correlates with cerebral perfusion. A series of clinical studies has demonstrated that the prefrontal theta cordance value decreases after 1 week of treatment in responders to antidepressants and that this effect precedes clinical improvement. Ketamine, a non-competitive antagonist of...
Bulletin of the Chemical Society of Japan
December 1, 2009
Takeshi Yokoyama, Reiko Yokoyama, Satoshi Nomura et al.
15 citations
Abstract The stereocenter in the intermediate alcohol (86% ee), created by enantioselective oxazaborolidinone-promoted aldol reaction, was transferred to the stereocenter in the cyclohexanone ring, necessary for (S)-ketamine, via allyl cyanate-to-isocyanate rearrangement. The second asymmetric synthesis of (S)-ketamine has been achieved (87% ee).
European Journal of Pain
November 8, 2009
Nora M. Hagelberg, Marko A. Peltoniemi, Teijo I. Saari et al.
55 citations
BACKGROUND: Oral ketamine is used as an adjuvant in the treatment of refractory neuropathic and cancer-related pain. Drug interactions may alter the analgesic or other effects of ketamine. AIM AND METHODS: The aim of the study was to investigate the effect of cytochrome P450 3A enzyme inhibition with clarithromycin on the pharmacokinetics and pharmacodynamics of oral S-ketamine in a randomized...
Anesthesiology
September 18, 2009
Marnix J. Sigtermans, Albert Dahan, René A. G. Mooren et al.
152 citations
BACKGROUND: Low-dose ketamine behaves as an analgesic in the treatment of acute and chronic pain. To further understand ketamine's therapeutic profile, the authors performed a population pharmacokinetic-pharmacodynamic analysis of the S(+)-ketamine analgesic and nonanalgesic effects in healthy volunteers. METHODS: Ten men and ten women received a 2-h S(+)-ketamine infusion. The infusion was...